Fig. 2From: Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumabThe receiver operating characteristic (ROC) curve for the risk factors postmenstrual age and neutrophil count at the first treatment. The area under the curve is 0.843 (95% CI: 0.770–0.916, P < 0.001)Back to article page